バイオケミカル酵素の変化に対するリポプロテインアフェレスの影響:体系的なレビューとメタ解析

Alireza Hatami¹, Masoud Eslami¹, Saeed Aslani²

¹Department of Hematology and Blood Transfusion, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Journal of clinical apheresis

|February 19, 2026

まとめ

リポプロテインアフェレス (LA) は重度の脂質不全症の治療に安全です. この治療は肝臓や筋肉の酵素を増加させず,いくつかのマーカーを低下させることもあり,生化学的安全性を支持する.

科学分野:

心臓病学心臓病学
バイオケミストリーバイオケミストリー
医療技術医療技術について

背景:

リポプロテインアフェレス (LA) は,重症で薬剤耐性型脱脂症の重要な治療法です.
臨床医はLA中に肝臓と筋肉の酵素をモニタリングし,負傷と間違えられる可能性のある生化学的シフトのために.

研究の目的:

循環中の肝臓および筋肉酵素レベルに対するリポプロテインアフェレスセッションを繰り返し行うことの効果に関する証拠を合成する.
LA治療が臓器損傷の生化学的マーカーに影響するかどうかを明確にするために.

主な方法:

観察的なヒト研究のためのPubMed,Scopus,Web of Scienceの体系的な文献検索.
アフェレス前・後の酵素値 (AST, ALT, ALP, GGT, LDH, CPK) を報告した研究を含む.
酵素レベルの変化を評価するために,加重平均差 (WMD) を使用した定量合成.

主要な成果:

プール分析により,アフェレシス後のAST,ALP,LDH,CPKのレベルが大幅に低下することが明らかになった.
アラニンアミノトランスフェラーゼ (ALT) とガンマグルタミルトランスフェラーゼ (GGT) のレベルは有意な変化を示さなかった.
リポプロテインアフェレシスは,繰り返しセッションで肝臓または筋肉損傷のマーカーを上昇させませんでした.

結論:

リポプロテインアフェレシスは,好ましい生化学的安全性プロファイルを示しています.
この研究では,アフェレス中の一時的な酵素シフトは慎重に解釈すべきであると示唆しています.
LAは特定の酵素マーカーの控えめな減少と関連しており,脂質不全症の管理における安全性を強化しています.

キーワード:

生化学酵素バイオケミカル酵素ディスリピデミア (Dyslipidemia) とはリポプロテインアフェレシスアフェレスメタアナリシスメタアナリシス重量平均差の差は,重量平均の差である.

さらに関連する動画

07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

478

関連する概念動画

01:26

Atherosclerosis III: Management

465

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

465

01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

659

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

659

01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

223

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

223

01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

270

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

270

01:30

Atherosclerosis I: Introduction

1.5K

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

1.5K

01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

295

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

295

関連する実験動画